Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1793 participants
OBSERVATIONAL
2020-11-01
2022-04-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Telbivudine in Chronic Hepatitis B Patients
NCT01958229
Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.
NCT06347588
Study of Telbivudine in Chronic Hepatitis B
NCT00970216
Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection
NCT03248622
Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B
NCT01743079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hepatitis B virus infected patients receiving corticosteroids for COVID-19 pneumonia
Hepatitis B virus infection
anti-hepatitis B virus core antigen positive serologic status
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hepatitis B virus infection
anti-hepatitis B virus core antigen positive serologic status
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* supplemental oxygen
* treated with corticosteroids for COVID-19 pneumonia
Exclusion Criteria
* hospitalized for medical conditions unrelated to COVID-19
* received corticosteroid therapy for non-COVID-19 reasons
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Centre Ljubljana
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HBV in covid
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.